Launches

Beachbody offers supplement sales using health savings accounts; PlantX, Boka launches oral health supplements; supplements take Form from RTE meal provider Factor; LIV3 JV behind marketing SugarShield; Ghost among Keurig Dr Pepper brands; and Nutra-Med Packaging expands with Legacy Pharma.

With its two biggest sellers losing exclusivity in 2028, the pressure is on for Bristol Myers Squibb to grow revenue through new products, which made meaningful contributions in Q3.

All eyes are on Eylea, after Amgen said last week that it would launch the first US biosimilar in the face of ongoing litigation. The California-based player has spoken of its prospects in the wet-AMD space, including a desire to chart its own path amid supply shortages for Avastin.

Sandoz has indicated that Amgen’s recently-announced at-risk US launch of a rival to Eylea doesn’t change its thinking around launch timing for its own FDA-approved aflibercept biosimilar.

Reckitt backs up prediction for strong sales during current quarter with advertising featuring a beauty queen and a line extension for Mucinex, one its strongest US consumer health product lines.

Fresenius Kabi has claimed another first for its Tyenne biosimilar rival to Actemra, becoming the debut challenger to the rheumatoid arthritis treatment to launch in Canada.

Lupin will benefit from 180 days of competitive generic therapy exclusivity as it launches the first and only US rival to the $200m brand Pred Forte.

Bayer adds dry eye treatment to its Bepanthen skin care range; Stada launches special edition Elotrans supplement for Eintracht Frankfurt fans; Hermes offers chewable magnesium supplement; and Klosterfrau introduces Oyono Night extension to help troubled sleepers maintain their immunity.

Arexvy has become the first RSV vaccine to show it can provide protection over three years – but that might mean lower market uptake than originally expected.

ProBiotix Health has announced two commercial partnerships for the distribution of its probiotic ingredients, with Deutsch-Pharm in Ukraine and Eifron in Greece respectively.